AAADV Workshop Chair Kim Lyerly on why the Workshop is unique: “It’s an open discussion with all the stakeholders in the drug development process on how to improve the whole process and make it better.”
Related Posts
2019 Pre-Workshop
A Message from the Co-Chairs of the FDA-Duke Global Regulatory Workshop
Welcome to this workshop!Cancer remains a serious global health threat. Oncology drug development has continued to lead other therapeutic areas in addressing the highly unmet medical needs of the cancer patients and their treatment, attested Read more…
2018 AAADV Workshop
Challenges with Novel Clinical Trial Designs: Master Protocols.
As seen on https://www.ncbi.nlm.nih.gov/pubmed/30696689 Cecchini M1, Rubin EH2, Blumenthal GM3, Ayalew K4, Burris HA5, Russell-Einhorn M6, Dillon H7, Lyerly HK8, Reaman GH9, Boerner S10, LoRusso PM10. The 2018 Accelerating Anticancer Agent Development (AAADV) Workshop assembled a panel of experts for an in-depth discussion session to Read more…